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Abstract
Many therapies have been proposed for the management of neuropathic pain, and they include the use of different 
antiepileptic drugs. However, the lack of high quality studies indicates that results on the different neuropathic 
disorders under study do not recommend a particular drug treatment. This study makes a systematic review of 
the published literature on the use of several antiepileptic drugs to treat neuropathic pain, and has the objective of 
considering both its clinical characteristics and pharmacological use, which will depend on their level of scientific 
evidence and will follow the principles of evidence-based dentistry. The articles were stratified according to 
their scientific evidence using the SORT criteria (Strength of Recommendation Taxonomy), and it included those 
articles that only have level 1 or 2. Randomized clinical trials were stratified according to their level of quality 
using the JADAD scale, an instrument described by Jadad et al. (7). to assess the quality of clinical trials, while 
studies with a level below 3 were discarded.  Recently, type A or B recommendations are given in favor or against 
the use of antiepileptic drugs to treat neuropathic pain on the basis of their scientific quality.
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Introduction
Neuropathic pain (NP) has been described by the 
International Association for the Study of Pain as a pain 
that is triggered or caused by a primary lesion in the 
nervous system. A common clinical feature is the lack 
of a source of nociception. The pain originated inside the 
nervous structure, and the somatic structures are normal. 
NPs are usually associated with different neurological 
symptoms such as burning, hyperalgesia, dysesthesia, or 
sometimes anesthesia. NP may appear in the form of an 
episodic or continuous pain (1).
NP can be caused by infections, trauma, metabolic abnor-
malities, chemotherapy, surgery, radiations, neurotoxins, 
nerve compression, inflammation and tumor invasion. As to 
episodic NP, there are different types of neuralgias, such as 
trigeminal neuralgia , glossopharyngeal neuralgia, genicu-
late neuralgia and neurovascular pain. And as to continuous 
NP,  the following conditions can be found: peripherally me-
diated pain (entrapment, deafferentation and neuritic pain), 
central mediated pain (burning mouth syndrome, atypical 
odontalgia, post-herpetic neuralgia) and metabolic neuropa-
thies (1).
NP is, regardless of its being central or peripheral, char-
acterized by a neuronal hyper-excitability in the injured 
areas of the nervous system that may have many charac-
teristics in common with some cellular changes that occur 
in certain forms of epilepsy (2-5).
Carbamazepine and phenytoin were the first anticonvulsants 
used in clinical controlled trials. Some studies have shown 
that these drugs relieve paroxysms in trigeminal neuralgia. 
Other studies have reported that gabapentin and pregabalin 
are effective in diabetic and mixed neuropathies, and in 
post-herpetic neuralgia (2-5).   
Lamotrigine, another anticonvulsant drug, has proved 
effective in trigeminal neuralgia and in post-stroke pain. 
Many of these drugs have been shown to reduce ectopic 
discharges in the affected nerve endings and neurons in the 
dorsal root ganglia by blocking sodium channels (2).
The most common side effects of anticonvulsants are drow-
siness and cerebellar symptoms (nystagmus, dizziness). 
Other side effects observed with carbamazepine and phen-
ytoin are hematological alterations and arrhythmia (2).
There are many drugs that can be used for the treatment of 
NP, such as carbamazepine, oxcarbazepine, pregabalin, 
topiramate, gabapentin, clonazepam, lamotrigine, 
phenytoin, tiagabine and valproic acid. In addition to 
their antiepileptic properties, these drugs has been used 
in the treatment of painful and chronic condition, NP 
included. 
Therefore, the aim of this articles is, on account of  the 
large amount of published literature on the treatment of 
NP, to make a systematic review on the use of different 
anticonvulsants for the treatment of NP, and on the basis 
of their level of scientific evidence and the observance of 
the principles of evidence-based dentistry. 
Material and Methods
A search on articles published by both MEDLINE and 
COCHRANE was carried out  between the years 1966 
to 2010. The MeSH (Medical Subject Heading) keywords 
and headings used were the following entries: “trigeminal 
neuralgia”, “glossopharyngeal neuralgia”, “post-herpetic 
neuralgia”, “persistent idiopathic facial pain” (which 
included “atypical odontalgia”, “phantom tooth pain” and 
“atypical facial pain”) and “burning mouth syndrome”. 
A similar search was made for each of the following 
terms: “carbamazepine”, “oxcarbazepine”, “pregabalin”, 
“topiramate”, “gabapentin”, “etiracetam”, “clonazepam”, 
“lamotrigine”, “phenytoin”, “tiagabine”, “vigabatrin”, 
“valproic acid” and “phenobarbital”.  The literature data 
identified was then exclusively used in studies in humans, 
articles written in english, randomized clinical trials and 
systematic reviews. Both search strategies were in turn 
combined using the Boolean operator “AND”, as a way to 
link articles on different NPs and anticonvulsants drugs. 
The same process was used in the COCHRANE database 
of the Cochrane Oral Health Group. Three authors 
analyzed the articles to verify if those obtained in the 
search were pertinent to the issue under study. Irrelevant 
articles were discarded. Next, the authors independently 
stratified the scientific articles according to their level of 
scientific evidence (Table 1A), using the SORT criteria 
Assessing Quality 
of evidence                                        Definition 
Level 1 Good quality, patient-oriented evidence. SR/meta-analysis or RCTs with consistent findings. 
Level 2 
Limited-quality patient-oriented evidence. SR/meta-analysis of lower quality clinical trials or of 
studies with inconsistent findings.Lower quality clinical trial. Cohort study. Case-control study. 
Level 3 
Other evidence. Consensus guidelines, extrapolations from bench research, usual practice, opinion, 
disease-oriented evidence (intermediate or physiologic outcomes only), or case series for studies of 
diagnosis, treatment, prevention, or screening. 
Table 1. A Level of evidence from studies (6).
Systematic Review (SR). Randomized Clinical Trials (RCTs).
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(Strength of Recommendation Taxonomy), and  included 
those articles that only have SORT level 1 or 2 (6); 
they subsequently stratified randomized clinical trials 
(RCT) according to their quality level by using JADAD 
(Alejandro R. Jadad) criteria (7), and discarded articles 
with a level below 3. Later, the authors compared 
their results, which were discussed in the event of 
disagreement. If no consensus was possible with regard 
to the level of scientific evidence of any article, a fourth 
author was included in the discussion. Subsequently, and 
depending of the scientific evidence, a recommendation 
was given (Table 1B) either in favor or against the use of 
this medication for NP.
“pregabalin”, 3 articles; “gabapentin”, 3 articles; “to-
piramate”, 2 articles; “etiracetam”, 1 article; “clonaze-
pam”, 3 articles; “lamotrigine”, 4 articles; “phenytoin”, 
7 articles; and “valproic acid” 2 articles. Next, each ar-
ticle was analyzed to determine if they were pertinent to 
the issue under study. 
The 55 articles assessing  the effects of different drugs 
in the treatment of TN were analyzed according to both 
JADAD and SORT criteria, and only those articles with 
SORT evidence level 1 or 2, and RCTs with  JADAD 
level above 3 were included.
This analysis produced 10 articles, of  which two were 
systematic reviews and 8 were RTCs that dealt with the 
Strength of 
Recommendation
Basis for recommendation 
           A Consistent, good quality patient-oriented evidence 
           B Inconsistent or limited-quality patient-oriented evidence 
           C 
 Consensus, disease-oriented evidence, usual practice, expert opinion, or 
case series for studies of  diagnosis, treatment,  prevention, or screening 
Table 1. B Strength of recommendation grades (6).
Results
The search on both MEDLINE, using MeSH terms, and 
the COCHRANE database provided, at a general level, 
a bank of 84 articles. Sixty articles were discarded for 
not meeting the inclusion criteria.
Trigeminal Neuralgia (TN)
The search for “Trigeminal neuralgia” and each of the 
following drugs in the MEDLINE and COCHRANE 
databases  provided the following 55 articles:  “car-
bamazepine”, 27 articles; “oxcarbazepine”, 4 articles; 
effect of carbamazepine in the treatment of TN (Table 2).
In five placebo controlled studies by Killian and Fromm 
(8-12), the authors observed that 19 of 27 of patients with 
TN had a good response to the use of carbamazepine at 
a maximum dose of 1 g per day during a 5-day period 
when compared with placebo. Nicol (9) observed a good 
response using the same drug at a maximum dose of 2 g 
per day for 14 days.
The magnitude of pain relief could be observed in 2 placebo-
controlled studies (10,11). Campbell et al. (10) found that 
Author Drug Level of Quality(JADAD) 
Level of  evidence
(SORT)
Campbell et al. 1966 (10) Carbamazepine 4 2 
Rockliff  and Davis 1966 (12) Carbamazepine 4 2 
Killian and Fromm 1968 (8) Carbamazepine 4 2 
Nicol 1969 (9) Carbamazepine 3 2 
Sturman and O´Brien 1969 (11) Carbamazepine 3 1 
Vilming et al.1986 (15) Carbamazepine/Tizanidine 4 2 
Lindstrom and Lindblom 1987(14) Carbamazepine/Tocainide 4 2 
Lechin et al. 1989 (13) Carbamazepine/Pimozide 3 2 
Wiffen et al. 2005 (16) (systematic review - Carbamazepine) 1 
Jorns and Zakrzewska 2007 (17) (systematic review - Carbamazepine) 2 
Strength of recommendation 
Recommendation for the use of Carbamazepine in TN: A 
Table 2. Studies on trigeminal neuralgia.
Trigeminal Neuralgia (TN).
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the average reduction in pain intensity was about 58% 
compared with 28% when they used carbamazepine at a 
daily dose of 400-800 mg for two weeks.  Further, Sturman 
and O´Brien (11) found a pain reduction of TN in 72% of 
cases over a period of  24 hours using a maximum daily 
dose of 3 tablets of 200 mg of carbamazepine (Tegretol®); 
however, there were side effects in more than half of cases. 
Similarly, Rockliff and Davis (12) published a placebo-
crossover study in which they reported the effectiveness 
of  carbamazepine  at doses of 200 mg three times a day 
to treat TN. 
An article by Lechin et al. (13) shows the different results 
of three active-controlled studies when comparing the use 
of carbamazepine with pimozide; they found that pimozide 
reduced TN symptoms in a greater proportion in TN 
patients, but had more side effects than carbamazepine. On 
the other hand, the authors of an active-controlled study (14), 
comparing carbamazepine with tocainide, found that both 
drugs produced a similar level of relief in TN-associated 
pain.  
Finally, in another active-controlled study in which Vil-
ming et al. (15) compared carbamazepine with tizanidine, 
the authors found a greater pain relief with carbamazepine 
in patients with TN;  however they observed that tizani-
dine was better tolerated and had lower side effects than 
carbamazepine. Nevertheless, they concluded that tizani-
dine could not be considered effective for the treatment of 
TN because there was a rapid reemergence of symptoms 
as soon as the treatment was discontinued. 
Finally, 2 systematic reviews on the pharmacological 
management of TN, published by Wiffen et al. (16) and 
Jorns et al. (17), concluded that carbamazepine is a drug of 
first choice because it has proven effective in the treatment 
of TN. However, both reviews highlighted that there is 
need for more high-quality studies to draw conclusions 
based on evidence on the management of TN.
Glossopharyngeal Neuralgia (GN)
The search for “glossopharyngeal neuralgia” and each of 
the following drugs: “carbamazepine”, “oxcarbamazepi-
ne”, “pregabalin”, “gabapentin”, “topiramate”, “etirace-
tam”, “clonazepam”, “lamotrigine”,  “phenytoin”,  “vi-
gabatrin”,  “phenobarbital”  and “valproic acid” in both 
MEDLINE and COCHRANE databases provided no re-
levant articles that met the search criteria of this study.
Post-herpetic Neuralgia (PHN)
The search for “post-herpetic neuralgia” and each of the 
following drugs: “carbamazepine”, “oxcarbamazepine”, 
“pregabalin”, “gabapentin”, “topiramate”, “etiracetam”, 
“clonazepam”, “lamotrigine”, “phenytoin”, “vigabatrin”, 
“phenobarbital”  and “valproic acid” in MEDLINE and 
COCHRANE databases provided 23 articles: 3 articles 
on “carbamazepine”, 2 articles on “oxcarbamazepine”, 
8 articles on “pregabalin”, 6 articles on “gabapentin”, 1 
article on “clonazepam”, 2 articles on “lamotrigine”, 1 
article on “phenytoin”.
Next, the 23 articles were analyzed to determine if 
they were pertinent to the issue under study. After 
this process 14 relevant articles remained under study: 
8 randomized clinical trials, 4 systematic reviews, 1 
pooled analysis and 1 retrospective study (Table 3). The 
Author Drug Level of Quality 
(JADAD) 
Level of evidence 
(SORT)
Rosenberg  et al. 1997 (30) Gabapentin - 2 
Rowbotham et al. 1998 (25) Gabapentin 5 1 
Rice and Maton 2001 (24) Gabapentin 5 1 
Dworkin et al. 2003 (18) Pregabalin 5 2 
Sabatowski  et al. 2004 (20) Pregabalin 5 2 
Freynhagen  et al. 2005 (19) Pregabalin 3 2 
Kochar  et al. 2005 (31) Valproic Acid 4 1 
van Seventer  et al. 2006 (22) Pregabalin 3 2 
Stacey et al. 2008 (21) Pregabalin 3 2 
Mellegers et al. 2001 (27) (systematic review - Gabapentin) 2 
Parsons et al. 2004 (28) (pooled analysis - Gabapentin) 2 
Plaghki et al. 2004 (29) (systematic review - Carbamazepine / Gabapentin) 2 
Wiffen et al. 2005 (26) (systematic review - Gabapentin) 2 
Moore  et al. 2009 (23) (systematic review - Pregabalin) 2 
Strength of recommendation 
Recommendation for the use of Gabapentin in PHN: A 
Recommendation for the use of Pregabalin in PHN: A 
Recommendation for the use of Valproic Acid in PHN: A
Table 3. Studies on post-herpetic neuralgia. 
Post-herpetic Neuralgia (PHN).
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14 articles assessing the effects of different drugs in the 
treatment of PHN were analyzed according to JADAD 
and SORT criteria, and only those articles with SORT 
evidence level 1 or 2, and RCTs  with  JADAD levels 
above 3 were included in the study.
Five placebo-controlled RCTs (18-22) assessed the 
effect of pregabalin to treat the PHN. Doses of 150 
mg, 300 mg, 450 mg or 600 mg were found to reduce 
pain significantly as well as provide a rapid and lasting 
response. However, in a systematic review published by 
Moore et al. (23), the authors found that even though 
pregabalin is not effective at doses of 150 mg, it could 
be more effective to treat PHN at doses of 600 mg. 
Nevertheless, the authors pointed out that
the highest benefit is obtained by an individualized 
treatment aimed at improving the response and 
minimizing the side effects.
 In one RCT with placebo, Rice and Maton (24) analyzed 
the effect of gabapentin in patients with PHN and they 
observed an improvement of pain within one week after 
starting treatment with a daily dose of 120 mg. They 
also found fewer cases of sleep disruption when quality 
of life improved.
On the other hand, a multicenter RCT reported an 
improvement of symptoms after the second week of 
treatment to reach a maximum improvement at the 
fourth week  with gabapentin at daily doses of 3600 
mg.. No changes in the response were observed at eight 
weeks of treatment.  Side effects included  drowsiness, 
dizziness, ataxia, peripheral edema and infection (25).
A review by Wiffen et al. (26) reported that gabapentin 
is effective for the treatment of  neuropathic pain in 
patients with PHN. However, the authors claim that 
there are other drugs, aside from gabapentin, that should 
be taken into consideration, such as carbamazepine and 
tricyclic antidepressants to treat PHN.
Similarly, the authors concluded in another review that 
gabapentin is effective in the treatment of neuropathic 
pain, but they also added that more studies are necessary 
to standardize doses and assess possible side effects (27). 
In a pooled analysis on three RCTs, Parson et al. (28), 
found that the most frequently side effects of gabapentin 
were dizziness, drowsiness and peripheral edema, which 
increased when doses were increased above 180 mg per 
day. However, dizziness and drowsiness  decreased 
when the dose was increased, and the peripheral edema 
increased when a maximum dose was administered.
On the other hand, a review published by Plaghki et al. 
(29) on  the pharmacological treatment of PHN reported 
that the studies included different population groups, and 
a large variability in both dose and design, a fact that 
made scientifically impossible to draw conclusions from 
the data obtained from comparisons between them. 
In a retrospective study on the treatment of neuropathic 
pain with gabapentin in 7 NPH patients, it was observed 
that an initial daily dose of 1600 mg increased to 2400 
per day yielded a 53% of pain reduction. The authors 
concluded that gabapentin can be used effectively in the 
treatment of PHN (30).
Finally, in a placebo-controlled RCT on the management 
of PHN with divalproex sodium, the authors observed 
a significant recovery in 58% of patients that receive 
this drug, while this recovery is comparable to that seen 
with  gabapentin, which produced fewer side effects (1 
patient). However, the authors concluded that more long 
term studies with more patients are needed to study the 
adverse effect of this drug in the long run (31).
Persistent Idiopathic Facial Pain (PIFP)
The search for “persistent idiopathic facial pain”, and 
“atypical odontalgia”, “phantom tooth pain” and “atypi-
cal facial pain”; as well as the drugs “carbamazepine”, 
“oxcarbamazepine”, “pregabalin”, “gabapentin”, “to-
piramate”, “etiracetam”, “clonazepam”, “lamotrigine”, 
“phenytoin”,  “vigabatrin”,  “phenobarbital”,  and “val-
proic acid” in both the MEDLINE and COCHRANE 
databases provided 2 articles: one article on “lamotri-
gine” and another article on “topiramate”. Immediately 
afterwards, both articles were analyzed to check if they 
were pertinent to the issue under study. The analysis did 
not provide any results, which indicated that there is an 
absence in the literature of good quality articles asses-
sing the pharmacological treatment of PIFP.
Burning Mouth Syndrome (BMS)
The search for “burning mouth syndrome” and each of the 
following drugs: “carbamazepine”, “oxcarbamazepine”, 
“pregabalin”, “gabapentin”, “topiramate”, “etiracetam”, 
“clonazepam”, “lamotrigine”, “phenytoin”, “vigabatrin”, 
“phenobarbital”  and “valproic acid” in both the 
MEDLINE and COCHRANE databases provided 4 
articles in total: 1 article on “carbamazepine”, 3 articles 
on “clonazepam”. Subsequently, the  4 articles were 
analyzed to check if they were pertinent to the issue 
under study. The process brought as a result, 1 relevant 
article (RCT) (Table 4).
The RCT analyzed the effect of topic clonazepam in 
patients with stomatodynia (BMS), and the authors find 
that the improvement of pain was significantly higher 
in the clonazepam group, with a significant decrease of 
50% in pain. However, this treatment was not effective 
in all patients, although the reasons underlying this fact 
Author Drug 
Level of Quality 
(JADAD) 
Level of Evidence 
(SORT)
Gremeau - Richard et al. 2004 (32) Clonazepam (topic) 5             1 
Strength of Recommendation 
Recommendation for the use of  topic Clonazepam  in BMS: A 
Burning Mouth Syndrome (BMS).
Table 4. Study for burning mouth syndrome.
Med Oral Patol Oral Cir Bucal. 2012 Sep 1;17 (5):e786-93.                                                                                                                                                      Antiepileptic drugs for neuropathic pain
e791
are unknown. The authors concluded that it is essential 
to deepen our knowledge about the patho-physiological 
mechanisms of BMS to be able select the best treatment, 
which includes the topical application of clonazepam 
and the development of new treatments involving 
different mechanisms of action. Also, it is necessary to 
make more high quality studies on the management of 
this syndrome in order to be able to obtain guidelines on 
evidence-based treatments, as well as a on good quality 
patient-oriented evidence (32).
Discussion 
Anticonvulsants were first used for the treatment of 
NP as determined by the characteristics of temporal 
profiles and abrupt nature of the painful attacks of this 
disease, which has similar characteristics to those seen 
in epileptic seizures (4).
Several studies have supported the use of anticonvulsants 
for the NP treatment (10 -15). In this review we found 
that carbamazepine is widely used for the TN treatment. 
We observed that  in the study of Lindstrom and 
Lindblom (14) the dose  varies from 100 mg. (10), 200 
mg. (12), 400 mg. and 1 g. (8), to a maximum tolerated 
dose of 20 mg/ kg. 
Most of the authors found better results in the treatment 
of TN with carbamazepine when it was compared with 
placebo (8-12). However, in 3 studies comparing the 
effect of this medication with other drugs they obtained 
different results. Lindstrom and Lindblom (14) compared 
carbamazepine with tocainide and obtained similar results 
in pain relief;  Lechin et al. (13), obtained a greater pain 
relief with pimozide than with carbamazepine; Vilming et 
al. (15), compared carbamazepine with tizanidine and they 
found that carbamazepine was more effective. Nowadays 
there are no guidelines about a standard dose for the 
treatment of TN, suggesting that the dose would be related 
to the patient’s needs and response.
However, as we have seen in this review on the NT 
treatment, carbamazepine is a drug of first choice. The 
control and monitoring of these patients is of the utmost 
interest (4). Oxcarbazepine should be administered as 
a second-choice drug in those cases when there is a 
poor control of the pain, or adverse effects occur (10). 
Because studies included in this review on the TN 
treatment show consistent evidence, the strength of 
recommendation for the use of carbamazepine in the 
TN is type A.
As we observed, there are no high quality studies 
evaluating the effect of newer drugs for the treatment 
of NP and especially the TN. For the PHN treatment 
with gabapentin, Rosenberg et al. (30), administered a 
maximum dose of 2400 mg per day and observed a pain 
reduction close to 53% of patients with PHN, so they 
concluded that gabapentin could be used effectively.
Rice et al. (24) carried out a clinical trial on the PHN 
treatment with gabapentin at different doses. They found 
more effective results in pain reduction with doses of 
1200 mg; therefore, they concluded that gabapentin is 
effective at doses of 1200 mg per day in the control of 
PHN-induced pain, and also observed an improvement 
of sleep quality and quality of life in these patients.
In another study, the authors observed progress of PHN 
patients treated with gabapentin at doses of 3600 mg 
per day, as well as a good response in 43% of the 229 
patients enrolled in the study (25).
In a review on the pharmacologic management of 
patients with PHN, the authors reported that gabapentin 
was effective at daily doses of 1800 mg and 2400 
mg. However, the authors report side effects, such 
as dizziness and drowsiness. So they concluded that 
gabapentin is both safe and effective and could be used 
routinely (29).
However, in a pooled analysis of adverse effects detected 
in three clinical trials, which included patients with post-
herpetic neuralgia, Parson et al. (28) observed that the 
incidence of peripheral edema increased when the dose 
exceeded 1800 mg per day and also that the commonest 
side effects were, in a transient manner, dizziness and 
drowsiness. They concluded that gabapentin is safe and 
does not have any inconveniences that may limit this 
dose to achieve an optimum efficacy (28).
Finally, in a review by Mellegers et al. (27), the authors 
conclude that this drug is effective, but its efficacy may 
be  reduced if it is administered at very low doses. On 
the other hand, they point out that when doses are rapidly 
increased, CNS adverse effects do also increase.  
As we observed in this review, gabapentin has been 
rated by several quality studies as the drug of choice 
for the treatment of PHN patients. All studies reported 
significant pain relief, improved quality of life and 
sleep, which therefore shows that it is an effective drug. 
However,  it should be administered gradually to reduce 
side effects (24).
So, bearing in mind the consistent evidence found in the 
studies, the strength of recommendation that we suggest 
for the use of gabapentin in the treatment of PHN is 
type A.   
It was observed that pregabalin produced a significant pain 
relief in the treatment of PHN patients. Doses varied and 
pain relief was significant in all cases (18–22). Nevertheless, 
Moore et al. (23) found in their systematic review that daily 
doses at 150 mg are not effective, although 600 mg doses 
per day are indeed effective for pain relief, but present 
more side effects (dizziness and drowsiness). The authors 
recommend a flexible-dosing regimen aimed at adjusting 
drug doses and optimizing their safety and efficacy 
(19). So, the strength of recommendation for the use of 
pregabalin in the treatment of PHN patients is, on account 
of the consistent evidence shown in the studies, type A.
There are few studies documenting the effectiveness of 
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valproic acid (VA) in the treatment of neuropathic pain 
(4). In this review we only found one high quality RCT 
assessing the effect of VA in PHN. Kochar et al. (31) 
observed a significant pain reduction in most patients 
at doses of 1000 mg of divalproex sodium per day for 
8 weeks, so they concluded that valproic acid could be 
comparable to gabapentin in its effectiveness to achieve 
pain relief; they also manifest that this drug has a 
good tolerance and could used as an alternative drug 
to gabapentin. However, they also added that further 
studies with more patients and longer duration will be 
needed to assess the effects of valproic acid in the long 
run.
The strength recommendation for the use of valproic 
acid in the treatment of PHN is, on account of the 
consistent evidence shown by the studies show, type A.
 As to BMS, we only found one high-quality article that 
assessed topical application of clonazepam (chewable 
tablets of 1 mg of clonazepam held in the mouth for 3 
minutes). The authors found pain relief to be about of 
50% when compared with placebo; however, they found 
that not all patients responded with the same the same 
level of efficiency, a fact that would result in the need 
for more quality studies aimed at evaluating the effects 
of topical clonazepam to treat BMS (32).
The strength recommendation for the use of topical 
clonazepam in the BMS is, on the basis of this high-
quality study, type A.
As for other NPs, such as GN and PIFP, we did not find 
any high-quality studies on the use of any specific drug 
to treat this disorders.
In conclusion, carbamazepine is the first drug of choice for 
the treatment of TN. Our recommendation is, with regard 
to the consistent evidence found in the studies, type A. 
As to the treatment of PHN, we have a good number of 
high-quality studies that assess the effects of three drugs 
(gabapentin, pregabalin and valproic acid); all of them 
have been found to be effective in the relief of symptoms, 
so the strength recommendation for pregabalin, pregabalin 
and valproic acid is, as determined by the aforementioned 
high-quality studies, type A. As for the treatment of BMS, 
we found one high-quality study that demonstrates the 
effectiveness of topical clonazepam in the treatment of this 
disease, so our recommendation for the use of this drug in 
BMS is, on the basis of abovementioned study, type A.
Our recommendations are based on quality studies; 
however, the design of them is variable, so it would 
be necessary a standardization of designs to carry out 
valuable comparative analyses in future studies.
We also observed that there is a need for higher-quality 
studies that may assess the effectiveness of the different 
anticonvulsants used in the treatment of NP, and thus be 
able to make a comparative study between the different 
drugs. 
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